Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;33(6):1395-402.
doi: 10.2337/dc10-0555.

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation

Michael Pignone  1 , Mark J Alberts, John A Colwell, Mary Cushman, Silvio E Inzucchi, Debabrata Mukherjee, Robert S Rosenson, Craig D Williams, Peter W Wilson, M Sue Kirkman; American Diabetes Association; American Heart Association; American College of Cardiology Foundation
Affiliations

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation

Michael Pignone et al. Diabetes Care. 2010 Jun.

Erratum in

  • Diabetes Care. 2010 Sep;33(9):2129-31
  • Diabetes Care. 2011 Jan;34(1):247-8
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. A: Effect of aspirin on CHD events. Tests for heterogeneity: χ2=8.71, P=0.367, I2=8.2%. B: Effect of aspirin on risk of stroke in patients with diabetes. Tests for heterogeneity: χ2=11.0, P=0.20, I2=27.2%. BMD, British Medical Doctors; CI, confidence interval; ETDRS, Early Treatment of Diabetic Retinopathy Study; HOT, Hypertension Optimal Treatment; JPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; PHS, Physicians' Health Study; POPADAD, Prevention of Progression of Arterial Disease and Diabetes; PPP, Primary Prevention Project; TPT, Thrombosis Prevention Trial; and WHS, Women's Health Study.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.
    1. Silva JA, Escobar A, Collins TJ, Ramee SR, White CJ: Unstable angina: a comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation 1995;92:1731–1736 - PubMed
    1. Natarajan A, Zaman AG, Marshall SM: Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diabetes and Vascular Disease Research 2008;5:138–144 - PubMed
    1. Reusch JE: Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose? J Clin Invest 2003;112:986–988 - PMC - PubMed
    1. Antithrombotic Trialists' (ATT) Collaboration. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849–1860 - PMC - PubMed

MeSH terms